Materials • NYSE
According to Zyberno, CLOROX CO /DE/ (CLX) is not a buy — AVERAGE BUSINESS (59/100) with a negative Margin of Safety of -100.0% and a Brina Gap of -12.2% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, CLOROX CO /DE/ (CLX) trades at $102.94 against an estimated intrinsic value per share of $45.07 — a -100.0% Margin of Safety based on Owner Earnings of $654.00M TTM, projected at -7.5% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -12.2% weakens the case: based on the company's ROIC (24.7%) and reinvestment rate (-17.2%), the business can fundamentally grow at -4.3% — but the current enterprise value implies the market expects 8.0%. This places CLX in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of -21.6% annually.
Over the trailing twelve months, CLX generated $654.00M in Owner Earnings. Capital was deployed as follows: $129.00M returned via share buybacks, $602.00M paid as dividends, $217.00M invested in capital expenditures. Reinvestment rate: -17.2%. Owner Earnings have declined at 7.5% annually over the trailing five years using log-linear regression.